XTLB
XTL Biopharmaceuticals Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.37
−1.25%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +19.1%
- EBIT
- +22.3%
- Net income
- —
- EPS
- —
- Free cash flow
- +38.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025